Neutrophil-dependent mediators of sepsis
Neutrophil-dependent mediators of sepsis
批准号:
9578653
负责人:
DAVID A. FORD
金额:
$29.53万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-01 至 2020-08-31
关键词:
AcidsAcute Renal Failure with Renal Papillary NecrosisAdult Respiratory Distress SyndromeAldehydesBacteriaBiological MarkersBiologyBloodBlood CirculationBlood PlateletsBlood VesselsCecumCell CommunicationCeramidesCessation of lifeClinicalCoculture TechniquesComplexDataEndothelial CellsEndotheliumEscherichia coliFailureFamilyFunctional disorderGlutathioneGoalsHumanHydrogen PeroxideHypochlorous AcidImmune responseIn VitroInfectionInjuryInterventionLeukocytesLipidsLungMediatingMediator of activation proteinMetabolicMicrobeModelingMolecular ProfilingMolecular TargetNADPH OxidaseNeutrophil ActivationOrganOrgan failureOutcomeOxidantsOxidesOxygenPathologyPennsylvaniaPeroxidasesPhagocytosisPharmacologyPhenotypePilot ProjectsPlasmaPlasmalogensProductionRattusResearch PersonnelRespiratory BurstRoleSaintsScientistSepsisSiteSpecimenSuperoxidesTechnologyTestingTherapeutic InterventionUniversitiesadductarmcandidate markerdesignendothelial dysfunctionextracellularin vivoindexinginnovationinterdisciplinary approachmetabolomicsmicrobial hostmicrobicidemortalityneutrophilnew therapeutic targetnoveloutcome predictionoxidationoxidized lipidresponsesample collectionseptic patientstargeted treatmentvascular endothelial dysfunction
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Sepsis strikes over one million in the US per year, with a mortality rate of 28-50%. Sepsis occurs when the
host response to microbes extends beyond the site of infection and into the systemic circulation. This results in
complex interactions involving microbes, blood components, and the endothelium that can progress to vascular
collapse and organ failure. Neutrophils are key early responders to infection. Neutrophil myeloperoxidase
(MPO) is a major mediator of oxygen-dependent microbicidal activity. MPO catalyzes the conversion of hydro-
gen peroxide to hypochlorous acid, which reacts with both microbial and host molecular targets to produce a
diverse array of oxidized lipids and metabolites. While neutrophil-derived oxidants promote microbe killing, they
also have a critical role in host injury. For the proposed studies the complexity of host and polymicrobial mo-
lecular targeting by neutrophil-derived oxidants will be investigated using both targeted and untargeted omics
to identify new biomarkers, mediators and mechanisms of sepsis-associated multi-organ failure. Thus, we will
test the hypothesis that neutrophil activation during sepsis leads to an oxidant-derived family of mole-
cules that mediate sepsis-associated multi-organ failure and are candidate biomarkers of human sep-
sis outcomes. This hypothesis will be tested with three specific aims. Specific Aim 1 will test the hypothesis
that lipid and metabolic molecular signatures of neutrophil activation mediate endothelial dysfunction in human
endothelial cells. There is a discovery arm to this aim to identify new molecular signatures of neutrophil activa-
tion. Discovered molecular signatures as well as those revealed in our pilot studies will be tested as mediators
of endothelial dysfunction and altered microbe killing. Specific Aim 2 will test the hypothesis that lipid and
metabolic molecular signatures of neutrophil activation are biomarkers and mediators of multi-organ failure in
rat sepsis. Pharmacological intervention will be used to examine the role of molecular signatures in outcomes
of rat sepsis as determined by survival, endothelial dysfunction and multi-organ failure. Specific Aim 3 will test
the hypothesis that novel molecular signatures of neutrophil activation associate with organ dysfunction and
death in human sepsis. A multi-PI group has been assembled for the proposed studies with each PI having
unique expertise. These PIs include the pioneer in the identification and biology of neutrophil-derived chlorin-
ated lipids, Dr. Ford; an established clinician scientist with expertise in clinical sepsis studies, Dr. Nuala Meyer;
and an expert in platelet, leukocyte, endothelial cell interactions and pathology, Dr. Jane McHowat. Overall, a
multi-disciplinary approach will examine the role of oxidized lipids and metabolites produced as a result of
neutrophil activation during sepsis as predictors of organ failure and mortality in human sepsis, and as media-
tors of vascular endothelial dysfunction examined both in vivo in the rat and in vitro to test mechanisms of
dysfunction. These innovative studies are designed to discover new paradigms for the role of neutrophils in
eliciting endothelial dysfunction providing new targets for therapeutics to treat septic patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Halolipid-Neutrophil Extracellular Trap Axis in Halogen Lung Injury
-
批准号:10685387
-
项目类别:
-
资助金额:$45.0万
-
财政年份:2022
-
负责人:DAVID A. FORD
-
依托单位:
Halolipid-Neutrophil Extracellular Trap Axis in Halogen Lung Injury
-
批准号:10507044
-
项目类别:
-
资助金额:$46.29万
-
财政年份:2022
-
负责人:DAVID A. FORD
-
依托单位:
Chlorinated lipid modification of proteins: Biomarkers of chlorine gas exposure
-
批准号:10160912
-
项目类别:
-
资助金额:$18.94万
-
财政年份:2020
-
负责人:DAVID A. FORD
-
依托单位:
Chlorinated lipids in sepsis
-
批准号:9132272
-
项目类别:
-
资助金额:$45.99万
-
财政年份:2015
-
负责人:DAVID A. FORD
-
依托单位:
Chlorinated lipids in sepsis
-
批准号:8944723
-
项目类别:
-
资助金额:$47.24万
-
财政年份:2015
-
负责人:DAVID A. FORD
-
依托单位:
Chlorinated lipids in sepsis
-
批准号:10378863
-
项目类别:
-
资助金额:$5.94万
-
财政年份:2015
-
负责人:DAVID A. FORD
-
依托单位:
Chlorinated lipids in sepsis
-
批准号:10210265
-
项目类别:
-
资助金额:$32.12万
-
财政年份:2015
-
负责人:DAVID A. FORD
-
依托单位:
Chlorinated Lipids in Myocardial Ischemia/Reperfusion
-
批准号:8227162
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2012
-
负责人:DAVID A. FORD
-
依托单位:
Chlorinated Lipids in Myocardial Ischemia/Reperfusion
-
批准号:8403793
-
项目类别:
-
资助金额:$17.85万
-
财政年份:2012
-
负责人:DAVID A. FORD
-
依托单位:
Serum chlorinated lipids as predictors of cardiovascular risk in lupus
-
批准号:7897511
-
项目类别:
-
资助金额:$22.95万
-
财政年份:2010
-
负责人:DAVID A. FORD
-
依托单位:
Serum chlorinated lipids as predictors of cardiovascular risk in lupus
-
批准号:8064785
-
项目类别:
-
资助金额:$18.91万
-
财政年份:2010
-
负责人:DAVID A. FORD
-
依托单位:
Novel MPO-derived plasma lipids as predictors of major adverse coronary events
-
批准号:7597135
-
项目类别:
-
资助金额:$18.38万
-
财政年份:2008
-
负责人:DAVID A. FORD
-
依托单位:
Novel MPO-derived plasma lipids as predictors of major adverse coronary events
-
批准号:7471172
-
项目类别:
-
资助金额:$22.05万
-
财政年份:2008
-
负责人:DAVID A. FORD
-
依托单位:
TSQ QUANTUM ESI-MS SURVEYOR BUNDLE: C.NEOFORMS, FUNGAL PATHOLOGY
-
批准号:6973461
-
项目类别:
-
资助金额:$6.78万
-
财政年份:2004
-
负责人:DAVID A. FORD
-
依托单位:
Plasmalogen-derived bioactive lipids in atherosclerosis
-
批准号:7258437
-
项目类别:
-
资助金额:$31.36万
-
财政年份:2004
-
负责人:DAVID A. FORD
-
依托单位:
Plasmalogen-derived bioactive lipids in atherosclerosis
-
批准号:6874978
-
项目类别:
-
资助金额:$33.08万
-
财政年份:2004
-
负责人:DAVID A. FORD
-
依托单位:
Plasmalogen-derived bioactive lipids in atherosclerosis
-
批准号:8213507
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2004
-
负责人:DAVID A. FORD
-
依托单位:
TSQ QUANTUM ESI-MS SURVEYOR BUNDLE: DRUG ABUSE
-
批准号:6973460
-
项目类别:
-
资助金额:$6.78万
-
财政年份:2004
-
负责人:DAVID A. FORD
-
依托单位:
TSQ QUANTUM ESI-MS SURVEYOR BUNDLE: DIABETES
-
批准号:6973458
-
项目类别:
-
资助金额:$6.78万
-
财政年份:2004
-
负责人:DAVID A. FORD
-
依托单位:
Plasmalogen-derived bioactive lipids in atherosclerosis
-
批准号:8042324
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2004
-
负责人:DAVID A. FORD
-
依托单位: